This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.
Keyphrases
- acute myeloid leukemia
- free survival
- allogeneic hematopoietic stem cell transplantation
- systematic review
- newly diagnosed
- locally advanced
- cerebrospinal fluid
- end stage renal disease
- squamous cell carcinoma
- type diabetes
- chronic kidney disease
- ejection fraction
- randomized controlled trial
- risk factors
- prognostic factors
- cardiovascular disease
- coronary artery disease
- patient reported outcomes
- rectal cancer
- combination therapy
- smoking cessation
- replacement therapy
- case control